Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Yu-Jang Chao, Jia-Horung Hung, Chang-Ping Lin, Hsi-Kung Kuo, San-Ni Chen, Yih-Shiou Hwang, Ko-Jen Li, Chun-Ju Lin, De-Kuang Hwang & Shwu-Jiuan Sheu. (2023) Diagnosis, Treatment, and Prevention of Noninfectious Acute Anterior Uveitis with or without Human Leukocyte Antigen B27 in Adults - Expert Consensus in Taiwan. Ocular Immunology and Inflammation 0:0, pages 1-8.
Read now
Read now
Sara Touhami, Julie Gueudry, Mathilde Leclercq, Valérie Touitou, Amine Ghembaza, Marie Hélène Errera, David Saadoun & Bahram Bodaghi. (2021) Perspectives for immunotherapy in noninfectious immune mediated uveitis. Expert Review of Clinical Immunology 17:9, pages 977-989.
Read now
Read now
Javier Loricera, Eva Galíndez-Aguirregoikoa & Ricardo Blanco. (2021) Safety of secukinumab for the treatment of active ankylosing spondylitis. Expert Opinion on Drug Safety 20:6, pages 627-634.
Read now
Read now
Huda Nadwi, Murad Janaini, Mohammed Zammo, Mohamed Cheikh & Hani Almoallim. (2020) New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis. International Medical Case Reports Journal 13, pages 331-334.
Read now
Read now
Carla Gaggiano, Jurgen Sota, Stefano Gentileschi, Valeria Caggiano, Salvatore Grosso, Gian Marco Tosi, Bruno Frediani, Luca Cantarini & Claudia Fabiani. (2020) The current status of biological treatment for uveitis. Expert Review of Clinical Immunology 16:8, pages 787-811.
Read now
Read now
Tanya Kowalski & Heather G Mack. (2020) Ocular complications of tumour necrosis factor alpha inhibitors. Clinical and Experimental Optometry 103:2, pages 148-154.
Read now
Read now
Diana Brixner, Manish Mittal, David T Rubin, Philip Mease, Harry H Liu, Matthew Davis, Arijit Ganguli & A Mark Fendrick. (2019) Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. Patient Preference and Adherence 13, pages 1545-1556.
Read now
Read now
Friederike Mackensen, Carsten Heinz, Eva Jakob, Viviane Grewing, Hanns-Martin Lorenz, Arnd Heiligenhaus, Regina Max & Matthias D. Becker. (2018) Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis. Ocular Immunology and Inflammation 26:7, pages 1015-1022.
Read now
Read now
Allan Gibofsky, Martha Skup, Manish Mittal, Scott J. Johnson, Matthew Davis, Jingdong Chao & David T. Rubin. (2017) Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Current Medical Research and Opinion 33:11, pages 1945-1953.
Read now
Read now
Julie Gueudry, Jennifer E. Thorne, Rakesh Bansie, Juergen Braun, P. Martin van Hagen & Bahram Bodaghi. (2017) Biologic Therapy for HLA-B27-associated Ocular Disorders. Ocular Immunology and Inflammation 25:2, pages 169-178.
Read now
Read now
Jürgen Braun, Xenofon Baraliakos & Uta Kiltz. (2016) Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy 16:5, pages 711-722.
Read now
Read now
Pilar Brito-Zerón, Roberto Perez-Alvarez & Manuel Ramos-Casals. (2015) Etanercept and uveitis: friends or foes?. Current Medical Research and Opinion 31:2, pages 251-252.
Read now
Read now
Articles from other publishers (43)
Bong-Woo Lee & Su-Jin Moon. (2023) Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment. International Journal of Molecular Sciences 24:14, pages 11662.
Crossref
Crossref
Ana Belén Azuaga, Julio Ramírez & Juan D. Cañete. (2023) Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences 24:5, pages 4901.
Crossref
Crossref
Henry S. Bison, Timothy M. Janetos, Hans M. Gao, David L. Zhang, Jessica Song & Brenda L. Bohnsack. (2023) Comparison of Uveitis Incidence by Medication in Juvenile Idiopathic Arthritis and Implications for Screening. American Journal of Ophthalmology 247, pages 70-78.
Crossref
Crossref
Maria Antonia De Francesco & Arnaldo Caruso. (2022) The Gut Microbiome in Psoriasis and Crohn’s Disease: Is Its Perturbation a Common Denominator for Their Pathogenesis?. Vaccines 10:2, pages 244.
Crossref
Crossref
Marina Salido Olivares & Estíbaliz Loza Santamaría. (2022) Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review. Seminars in Arthritis and Rheumatism 52, pages 151944.
Crossref
Crossref
Soo Min Ahn, Minju Kim, Ye-Jee Kim, Yusun Lee & Yong-Gil Kim. (2022) Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study. Journal of Clinical Medicine 11:3, pages 631.
Crossref
Crossref
Mahsaw Motlagh, Christopher Fortenbach, Howard I. Maibach & Bobeck S. Modjtahedi. (2021) Identifying and Treating Ocular Manifestations in Psoriasis. American Journal of Clinical Dermatology 23:1, pages 51-60.
Crossref
Crossref
Damien Roche, Martin Badard, Laurent Boyer, Pierre Lafforgue & Thao Pham. (2021) Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Research & Therapy 23:1.
Crossref
Crossref
Ulf Lindström, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T H Jacobsson & Johan Askling. (2021) Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?. Annals of the Rheumatic Diseases 80:11, pages 1445-1452.
Crossref
Crossref
Manish Mittal, Min Yang, Manan Shah, Wei Gao, Christopher Carley & Bruce W. Sherman. (2021) Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States. Journal of Occupational & Environmental Medicine 63:10, pages e724-e731.
Crossref
Crossref
Jérémie Sellam, Jacques Morel, Anne Tournadre, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Denis Jullien, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:2, pages 105174.
Crossref
Crossref
Gabrielle Fridman & KaraC LaMattina. (2021) New-onset anterior uveitis in two patients on ustekinumab for inflammatory bowel disease. Indian Journal of Ophthalmology - Case Reports 1:3, pages 522.
Crossref
Crossref
Elsa How Shing Koy, Pierre Labauge, Athan Baillet, Clément Prati, Hubert Marotte & Yves-Marie Pers. (2021) Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110258.
Crossref
Crossref
. (2020) Leitlinie Nr. 24a Uveitis intermediaGuidelines nr. 24a intermediate uveitis. Der Ophthalmologe 118:S1, pages 16-30.
Crossref
Crossref
Gustavo Gomes Resende, Eduardo de Souza Meirelles, Cláudia Diniz Lopes Marques, Adriano Chiereghin, Andre Marun Lyrio, Antônio Carlos Ximenes, Carla Gonçalves Saad, Célio Roberto Gonçalves, Charles Lubianca Kohem, Cláudia Goldenstein Schainberg, Cristiano Barbosa Campanholo, Júlio Silvio de Sousa Bueno Filho, Lenise Brandao Pieruccetti, Mauro Waldemar Keiserman, Michel Alexandre Yazbek, Penelope Esther Palominos, Rafaela Silva Guimarães Goncalves, Ricardo da Cruz Lage, Rodrigo Luppino Assad, Rubens Bonfiglioli, Sônia Maria Alvarenga Anti, Sueli Carneiro, Thauana Luíza Oliveira, Valderílio Feijó Azevedo, Washington Alves Bianchi, Wanderley Marques Bernardo, Marcelo de Medeiros Pinheiro & Percival Degrava Sampaio-Barros. (2020) The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019. Advances in Rheumatology 60:1.
Crossref
Crossref
Gisèle Khoury, Jacques Morel, Bernard Combe & Cédric Lukas. (2020) Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort. Arthritis Research & Therapy 22:1.
Crossref
Crossref
A. M. Dadalova, E. A. Vasilenko, R. R. Samigullina & V. I. Mazurov. (2020) Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis. Modern Rheumatology Journal 14:4, pages 165-170.
Crossref
Crossref
George E Fragoulis & Stefan Siebert. (2020) Treatment strategies in axial spondyloarthritis: what, when and how?. Rheumatology 59:Supplement_4, pages iv79-iv89.
Crossref
Crossref
Piotr Nehring & Adam Przybyłkowski. (2020) Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?. Pharmaceutical Medicine 34:4, pages 257-262.
Crossref
Crossref
Atul A. Deodhar, Corine Miceli‐Richard, Xenofon Baraliakos, Helena Marzo‐Ortega, Dafna D. Gladman, Ricardo Blanco, Ayan Das Gupta, Ruvie Martin, Jorge SafiJrJr, Brian Porter, Abhijit Shete & James T. Rosenbaum. (2020) Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatology 2:5, pages 294-299.
Crossref
Crossref
Nabil Bouzid, Yvan Jamilloux, Roland Chapurlat, Pierre Pradat, Audrey De Parisot, Laurent Kodjikian & Pascal Sève. (2020) Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. PLOS ONE 15:3, pages e0230560.
Crossref
Crossref
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards & Susanne Rohrer. (2020)
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3
MEASURE
3 Study
. ACR Open Rheumatology 2:2, pages 119-127.
Crossref
Crossref
Judith Rademacher, Denis Poddubnyy & Uwe Pleyer. (2020) Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2095173.
Crossref
Crossref
U. Kiltz, J. Braun, A. Becker, J.-F. Chenot, M. Dreimann, L. Hammel, A. Heiligenhaus, K.‑G. Hermann, R. Klett, D. Krause, K.‑F. Kreitner, U. Lange, A. Lauterbach, W. Mau, R. Mössner, U. Oberschelp, S. Philipp, U. Pleyer, M. Rudwaleit, E. Schneider, T. L. Schulte, J. Sieper, A. Stallmach, B. Swoboda & M. Winking. (2019) Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019Long version on the S3 guidelines for axial spondyloarthritis including Bechterew’s disease and early forms, Update 2019. Zeitschrift für Rheumatologie 78:S1, pages 3-64.
Crossref
Crossref
A. B. Demina. (2019) Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis. Modern Rheumatology Journal 13:4, pages 110-115.
Crossref
Crossref
Diana BrixnerDavid T. RubinPhilip MeaseManish MittalHarry LiuMatthew DavisArijit GanguliA. Mark Fendrick. (2019) Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. Journal of Managed Care & Specialty Pharmacy 25:7, pages 770-779.
Crossref
Crossref
Ashvini Reddy, Fauziyya Muhammad & Darren J. Lee. 2019. Advances in the Diagnosis and Management of Uveitis. Advances in the Diagnosis and Management of Uveitis.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Denis Poddubnyy, Paul Emery, Eumorphia M Delicha, Zsolt Talloczy & Brian Porter. (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology 58:5, pages 859-868.
Crossref
Crossref
Jakub Wroński & Piotr Fiedor. (2018) The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?. The Journal of Clinical Pharmacology 59:4, pages 445-462.
Crossref
Crossref
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef & Irene E. van der Horst-Bruinsma. (2019) Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study. The Journal of Rheumatology 46:2, pages 153-159.
Crossref
Crossref
Suhwan Lee, Yu Jeong Park & Joo Yong Lee. (2019) The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis. Journal of Korean Medical Science 34:42.
Crossref
Crossref
Ennio Giulio Favalli, Andrea Becciolini, Roberto Caporali, Monica Todoerti, Florenzo Iannone, Liliana Dinoia, Marco Sebastiani, Amelia Spinella, Elisa Gremese, Francesco Cianci, Fabiola Atzeni, Francesca Bandinelli, Gianfranco Ferraccioli & Giovanni Lapadula. (2018) The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews 17:12, pages 1251-1258.
Crossref
Crossref
Martina Biggioggero, Chiara Crotti, Andrea Becciolini, Elisabetta Miserocchi & Ennio Giulio Favalli. (2018) The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BioMed Research International 2018, pages 1-11.
Crossref
Crossref
Ulf Lindström, Tor Olofsson, Sara Wedrén, Ilia Qirjazo & Johan Askling. (2018) Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open 4:2, pages e000762.
Crossref
Crossref
Min Jung Kim, Eunyoung Emily Lee, Eun Young Lee, Yeong Wook Song, Hyeong Gon Yu, Yunhee Choi & Eun Bong Lee. (2018) Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis. Clinical Rheumatology 37:10, pages 2763-2770.
Crossref
Crossref
Yvan Jamilloux, David Saadoun & Pascal Sève. (2018) Re: Dick et al.: Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative (Ophthalmology. 2018;125:757-773). Ophthalmology 125:8, pages e53-e54.
Crossref
Crossref
L. Cabane, S. Baillif, B. Baldin, V. Breuil, L. Euller-Ziegler & N. Tieulié. (2018) Uvéites sous biothérapies et/ou DMARDs en rhumatologie : analyse de la base de données déclarative de la pharmacovigilance nationale française. Journal Français d'Ophtalmologie 41:4, pages 350-356.
Crossref
Crossref
Srilakshmi M. Sharma & Daniel Jackson. (2017) Uveitis in the Spondyloarthopathies. Best Practice & Research Clinical Rheumatology 31:6, pages 846-862.
Crossref
Crossref
Elisabeth Lie, Ulf Lindström, Tatiana Zverkova-Sandström, Inge C Olsen, Helena Forsblad-d'Elia, Johan Askling, Meliha C Kapetanovic, Lars Erik Kristensen & Lennart T H Jacobsson. (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Annals of the Rheumatic Diseases 76:9, pages 1515-1521.
Crossref
Crossref
David T. RubinManish MittalMatthew DavisScott JohnsonJingdong ChaoMartha Skup. (2017) Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Managed Care & Specialty Pharmacy 23:8, pages 859-867.
Crossref
Crossref
Douglas Wolf, Martha Skup, Hongbo Yang, Anna P. Fang, Andrew Kageleiry, Jingdong Chao, Manish Mittal & Mark Lebwohl. (2017) Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. Clinical Therapeutics 39:4, pages 849-862.e6.
Crossref
Crossref
Claudia Fabiani, Antonio Vitale, Giuseppe Lopalco, Florenzo Iannone, Bruno Frediani & Luca Cantarini. (2016) Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology 35:11, pages 2631-2638.
Crossref
Crossref
Philip Ian Murray & Saaeha Rauz. (2016) The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Practice & Research Clinical Rheumatology 30:5, pages 802-825.
Crossref
Crossref